Kenvue Inc. $KVUE Shares Sold by Credit Industriel ET Commercial

Key Points

• Credit Industriel ET Commercial reduced its stake in Kenvue (NYSE:KVUE) by 59.2% in Q4, selling 177,500 shares and leaving 122,500 shares valued at $2.113 million.
• Kenvue beat quarterly estimates with $0.27 EPS vs. $0.22 expected and $3.78 billion in revenue (up 3.2% YoY), and announced a quarterly dividend of $0.2075 (annualized $0.83) implying a 4.8% yield while carrying a payout ratio of 107.79%.

Credit Industriel ET Commercial reduced its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 59.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 122,500 shares of the company's stock after selling 177,500 shares during the period. Credit Industriel ET Commercial's holdings in Kenvue were worth $2,113,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KVUE. Arrowstreet Capital Limited Partnership acquired a new stake in Kenvue during the second quarter worth about $6,528,000. Jump Financial LLC increased its position in Kenvue by 210.6% during the second quarter. Jump Financial LLC now owns 54,823 shares of the company's stock worth $1,147,000 after purchasing an additional 37,170 shares during the last quarter. AXA S.A. increased its position in Kenvue by 21.1% during the second quarter. AXA S.A. now owns 48,892 shares of the company's stock worth $1,023,000 after purchasing an additional 8,524 shares during the last quarter. NewEdge Advisors LLC increased its position in Kenvue by 219.1% during the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company's stock worth $2,040,000 after purchasing an additional 66,930 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Kenvue by 0.6% during the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company's stock worth $39,217,000 after purchasing an additional 10,885 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE opened at $17.41 on Wednesday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The stock has a market cap of $33.42 billion, a PE ratio of 22.60, a P/E/G ratio of 3.89 and a beta of 0.55. The firm has a 50-day simple moving average of $17.70 and a two-hundred day simple moving average of $17.20. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business had revenue of $3.78 billion during the quarter, compared to analysts' expectations of $3.68 billion. During the same period last year, the business earned $0.26 earnings per share. The business's revenue for the quarter was up 3.2% on a year-over-year basis. As a group, analysts forecast that Kenvue Inc. will post 1.1 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be issued a $0.2075 dividend. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue's payout ratio is 107.79%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on KVUE shares. Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 14th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a "hold" rating in a research report on Wednesday, February 18th. Citigroup dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Wednesday, April 15th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Kenvue in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group cut shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.